VRDN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
284.0K
+101.4%
141.0K
+6.8%
132.0K
-99.8%
70.6M
+93993.3%
75.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
284.0K
+101.4%
141.0K
+6.8%
132.0K
-99.8%
70.6M
+93993.3%
75.0K
Operating Expenses
126.6M
+8.2%
117.0M
-4.8%
122.9M
+11.1%
110.6M
+3.5%
106.8M
R&D
71.6M
-7.8%
77.6M
-13.0%
89.2M
+3.4%
86.3M
-0.4%
86.6M
SG&A
55.0M
+42.1%
38.7M
+14.9%
33.7M
+38.4%
24.3M
+20.3%
20.2M
Operating Income
-126268000
-8.1%
-116841000
+4.8%
-122749000
-206.8%
-40013000
+62.5%
-106767000
EBITDA
-126151000
-8.1%
-116720000
+4.8%
-122629000
-207.3%
-39903000
+62.6%
-106654000
Net Income
-127119000
-21.2%
-104901000
+12.8%
-120355000
-247.9%
-34599000
+65.7%
-100735000
EPS (Basic)
$-1.05
-16.7%
$-0.90
+15.9%
$-1.07
-214.7%
$-0.34
+66.0%
$-1.00
EPS (Diluted)
$-1.05
-16.7%
$-0.90
+15.9%
$-1.07
-214.7%
$-0.34
+66.0%
$-1.00
Shares (Diluted)
107.9M
+5.5%
102.2M
+8.2%
94.5M
+15.5%
81.8M
+0.2%
81.6M
Viridian Therapeutics (VRDN) โ€” Financials